Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Adaptimmune Therapeutics's operating margin for the twelve months ending Jun 30, 2025 was -252.3%. For fiscal 2024 it was -38.6%, against -231.8% the year before. The highest annual figure on record is -38.6% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -38.6% | +193.2 |
| FY2023 | Dec 31, 2023 | -231.8% | +372.2 |
| FY2022 | Dec 31, 2022 | -604.0% | +2034.6 |
| FY2021 | Dec 31, 2021 | -2638.6% | +731.9 |
| FY2020 | Dec 31, 2020 | -3370.5% | +9086.7 |
| FY2019 | Dec 31, 2019 | -12457.2% | −12318.8 |
| FY2018 | Dec 31, 2018 | -138.4% | +74.8 |
| FY2017 | Dec 31, 2017 | -213.2% | +36.4 |
| FY2015 | Jun 30, 2015 | -249.6% | +1146.9 |
| FY2014 | Jun 30, 2014 | -1396.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -221.5% | −275.0 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -627.8% | +239.8 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -2281.8% | +19300.9 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -35.9% | +601.3 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | 53.6% | +929.0 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -867.6% | −871.1 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -21582.7% | −21335.7 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -637.1% | −23.6 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -875.4% | −85.4 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | 3.5% | +1401.5 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -247.0% | +2778.0 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -613.5% | +2892.8 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -790.0% | +480.1 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -1398.1% | +7332.1 |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -3025.0% | −527.4 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -3506.3% | −499.2 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -1270.2% | +4756.3 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -8730.2% | −4819.0 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -2497.5% | +1672.1 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -3007.1% | +13921.6 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -6026.5% | +16586.2 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -3911.2% | −1740.4 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -4169.6% | −4186.8 |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -16928.7% | −16609.2 |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -22612.7% | −22262.1 |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -2170.8% | −1475.2 |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | 17.2% | +35.4 |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -319.5% | +355.9 |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -350.7% | +427.1 |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -695.6% | −296.4 |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -18.2% | +187.3 |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -675.4% | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -777.8% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -399.1% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -205.5% | – |
See a number that looks wrong?